Skip to main content
OpenTrials
Completed

NCT Number: NCT01100476

Mynx M5 One Hour Ambulation Study

The Mynx Vascular Closure Device (Mynx M5) is a sponge-like material used to close the hole in the artery after patients undergo a diagnostic endovascular procedures

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Our Lady of Lourdes Medical Center

Camden, New Jersey, 08103, United States

About this study

Key Inclusion:

  • Patients >18 yrs of age
  • Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath via the common femoral artery.
  • Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for any reason) as assessed by investigator.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is > 18 years of age
  • Patient underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
  • Patient has been informed and understands the nature of the study and provides written INformed COnsent approved by the appropriate Institutional Review Board (IRB) prior to enrollment
  • Patient is able to ambulate (routinely walk 6 meters or 20 feet without assistance for any reason) as assessed by the investigator

Exclusion criteria

Pre-Procedure Exclusion Criteria

  • Patient had a prior surgical procedure, PTA, stent placement, or vascular graft in the common femoral artery
  • Patient has a bleeding disorder such as thrombocytopenia
  • Patient has uncontrolled hypertension
  • Patient is morbidly obese (BMI >40 kg/m2
  • Patient is pregnant or lactating
  • Patient has a documented INR >1.5 or patients currently receiving glycoprotein IIb/IIIa platelet inhibitor
  • Patient has a known severe allergy to contrast medium
  • Patient has a known allergy to PEG
  • Patient is unable to ambulate at one hour secondary to a co-morbid condition
  • Patient is know to require an extended hospitalization or re-hospitalization (e.g.patient is undergoing coronary artery bypass graft (CABG) surgery) or patient is scheduled to have a CABG surgery <30 days following the procedure

Intra-Procedure Exclusion Criteria

  • Common femoral artery is <5mm in diameter
  • Patient with clinically significant peripheral vascular disease in the vicinity of the puncture
  • Puncture site is located above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks
  • Patient has a posterior puncture or multiple punctures in an attempt to gain access
  • Patient has an ipsilateral venous sheath
  • Patient has a pre-existing arterial bleed/extravasation identified on pre-procedure femoral arteriogram, hematoma, pseudoaneurysm or arteriovenous fistula present prior to sheath removal
  • Patient has intra-procedural bleeding around the access site prior to sheath removal

Treatment and study plan

Endovascular Diagnostic Procedures

Device

Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery

Other names: Angiography

Primary outcomes

  1. Safety & Tolerability

    Time frame: Enrollment approx for 4 months

    To assess safety and tolerability of participants ambulating within one hour of placement of the Mynx M5 Closure Device. Participants will be assessed for adverse event occurrence for 30 +/-7 days.

Secondary outcomes

  1. Device success

    Time frame: 30 +/- 7days

    Assess device success, time to dischargeability, major and minor complications in all patients enrolled in the study

Sponsors and collaborators

Lead sponsor

Cardiovascular Associates of the Delaware Valley

Other

Collaborators

  • AccessClosure, Inc.

Registry information

Official study title

Single-center, Post Market, Prospective, Consecutive, Single-arm Study Compared to Historical Control (Diagnostic Arm of the Mynx 6/7F Study)

Acronym: Mynx

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Apr 9, 2010
Registry last updated
Feb 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.